These are the objectives of a new phase of the cooperation strategy between the two countries in science, technology, innovation, and the economic and industrial complex of health, where the concept of connecting these sectors prevails.
During this Tuesday’s session, the need to facilitate a greater environment of scientific collaboration and knowledge management was also approved, as raised by the vice president of health production and innovation in Brazil, Marco Aurelio Carneiro, with the experience of Fiocruz (the Oswaldo Cruz Foundation) and its National Climate and Health Observatory.
For her part, Julieta María Cardozo from the Studies and Projects Funder, Finep, shared the lines of financing and references for bilateral cooperation. In his speech, the general coordinator of strategic actions in clinical research of the Brazilian Ministry of Health, Evandro Oliveira, refers to the opportunities to improve the productive capacity and innovation of drugs, among other possibilities.
During the day, the director of clinical research at the Center for Molecular Immunology, Dr. Tania Crombet, explained that currently, among other studies, Cuba has initiated a clinical trial with the nasal formulation NeuroEpo for patients with mild and moderate Alzheimer’s disease.
This drug is very effective due to the remarkable improvement of those affected by showing a reduction in the development of cognitive impairment. It is also tested for the treatment of ataxias and has great potential in Parkinson’s, acute cerebral ischemias, and other neurodegenerative diseases.
With the reactivation of the Brazil-Cuba Binational Steering Committee, the two countries re-promote cooperation in health, science, innovation, and the regulatory area of medicines, equipment and medical devices.
Participating in the meeting were the Cuban Ministers of Public Health José Angel Portal, the Minister of Science, Technology, and Environment Eduardo Martínez, the Vice Minister of Health of Brazil Carlos Gadhela, and Christian Vargas, ambassador of that country in Havana, who agreed that this new phase of work marks a milestone in the field of health science.
Representatives of the biotechnology and pharmaceutical industries of the Caribbean island and the giant South American regulatory authority and clinical trial development authority also attended.
During the first day of work, the head of Citma presented the potential of the Cuban biotechnology and pharmaceutical conglomerate, the vaccine projects against pneumococcus, dengue, and human papilloma where some of its institutions are working, and the development of new products such as interferon, monoclonal antibodies, and other therapeutic immunogens that are used in the treatment of cancer.
He also mentioned the industry-leading products, where Heberprot-P stands out for the treatment of diabetic foot ulcers, given the incidence of the pathology in Latin America, and the wide portfolio of medicines of natural origin, which will benefit the population of Brazil. .
Vice Minister Gadhela pointed out Brazil’s interest in maintaining relations with Cuba for its contributions to improving the health indicators of his country and how the transfer of the technological platform 20 years ago favored the creation of Brazil’s first perfect vaccine against COVID-19.